Dr. Maier joined Alnylam Pharmaceuticals in 2006 where he currently serves as Vice President, Research heading the RNAi Discovery group and co-leading an interdisciplinary research team focused on RNAi platform technology. In these roles, Dr. Maier has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, and the advancement of multiple therapeutic programs to development, which culminated in the approval of ONPATTRO(TM), the first-ever RNAi therapeutic.

Martin received his Ph.D. in Organic Chemistry in 1997 at the University of Tübingen, Germany with Professor Ernst Bayer. He moved to the U.S. for his postdoctoral research at Isis (Ionis) Pharmaceuticals, where he subsequently assumed a permanent position working on novel chemistries and delivery systems for antisense oligonucleotides.

During Martin’s almost 20 years of experience in the field of oligonucleotide therapeutics, he has contributed to the advancement of therapeutic nucleic acids across both, ASO and RNAi platforms. He is the author of more than 70 peer-reviewed scientific publications, reviews and book chapters and inventor on more than 30 issued patents.

Affiliations

• Member of the Oligonucleotide Therapeutics Society
• Member of the American Chemical Society